Fragonomics: fragment-based drug discovery |
| |
Authors: | Zartler Edward R Shapiro Michael J |
| |
Affiliation: | Lilly Research Laboratories, Eli Lilly & Co., Indianapolis, IN 46285, USA. zartler_edward@lilly.com |
| |
Abstract: | The use of smaller molecules (fragments) in the drug discovery process has led to success in delivering novel leads for many different targets. This process is a highly integrated process, starting from library design to screening and medicinal chemistry. An overview of this process is presented with particular emphasis placed on the NMR aspect of screening. |
| |
Keywords: | |
本文献已被 PubMed 等数据库收录! |
|